Axe Compute sells Helomics cancer diagnostics unit to DataMEDS AI in all-stock deal
AGPU•Axe Compute divests Helomics cancer diagnostics lab business
Axe Compute sold its Helomics cancer diagnostics lab business to DataMEDS AI in an all-stock transaction dated Sept. 15, 2026.
Consideration comprised DataMEDS common shares and common share equivalents, leaving Axe Compute with an equity stake in DataMEDS.
The divestiture completes Axe Compute’s shift from its legacy oncology operations into a pure-play neocloud GPU-as-a-Service platform.
Related News
BlackRock Resources & Commodities Strategy Trust director Francis C. Mahoney files initial beneficial ownership statement
BCX•
BlackRock Health Sciences Term Trust director Francis C. Mahoney files initial beneficial ownership statement
BMEZ•
